- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00554281
Using Glucose Sensors to Prevent Hypoglycemia
Paradigm Real Time Continuous Glucose Monitoring Device for the Prevention of Hypoglycemia
Hypoglycemia is the most common complication of Type 1 diabetes particularly in those who strive for good glycemic control. In some patients there is a loss of awareness of hypoglycaemia so that the first manifestation of hypoglycaemia may be confusion or coma. Such a situation may carry risks that the patient may harm him or her self. Medtronic has recently developed a continuous glucose sensor that determines the glucose level every 3 minutes using a subcutaneous sensor and transmits the information to a remote device (Paradigm RT) that may be worn or left close by eg on a bedside table. The device may be programmed to alarm for a rapidly falling glucose or for low glucose levels.
We propose to use this in 16 patients with severe hypoglycemia as evidenced by a high HYPO score and see if we can decrease the number of hypoglycemic reactions and document this improvement with a better HYPO score.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sixteen patients with Type 1 diabetes (as defined by: onset under the age of 25, lean at time of onset, continuous insulin use, and/or history of ketoacidosis and C-peptide negative), with a HYPO score over the seventy-fifth percentile (>423), will be approached and offered the study.
The study will be conducted over a three month time-frame. The first month will be a run-in period for participants to collect four weeks of glucose readings and information about their hypoglycemic events. These records will be used to calculate the baseline modified HYPO score. Patients will be screened during the first month for thyroid disease, celiac disease and Addison's disease.
During the second month they will meet with the study nurse for an intensive instruction period on the use of the Paradigm RT sensor. They will spend this month practicing to use the sensor and confirming they can use it adequately.
During the final month they will wear the sensor and collect glucose and hypoglycemia records for calculation of the final modified HYPO score.
The end point will be the change from the baseline modified HYPO score to the final four week HYPO score and this would be used to identify any improvement.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
Edmonton, Alberta, Canada, T6G 2S2
- University of Alberta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 Diabetes Mellitus confirmed by C-peptide <0.10 nmol/L
- age 18 - 70 yrs.
- HYPO score >423
- normal TSH, serum cortisol and anti-transglutaminase (ATTG)
Exclusion Criteria:
- current diagnosis of cancer
- planning a pregnancy
- Inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: B
|
Use glucose sensor to prevent episodes of severe hypoglycemia
Other Names:
|
No Intervention: A
Run in period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Decrease in HYPO score
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of episodes of severe hypoglycemia
Time Frame: 3 months
|
3 months
|
Number of patients who decide to continue using the device
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edmond A Ryan, MD, University of Alberta
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UAHREB6344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
University of UlmRecruitingHypoglycemia, ReactiveGermany
-
University of ArizonaNot yet recruiting
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Zealand University HospitalUnknownHypoglycemia, ReactiveDenmark
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
-
Vogenx, Inc.CompletedPostbariatric HypoglycemiaUnited States
-
Stanford UniversityCompletedNeonatal HypoglycemiaUnited States
-
Diva De LeonLester and Liesel Baker FoundationCompletedPostprandial HypoglycemiaUnited States
Clinical Trials on Use of glucose sensor (Paradigm Guardian)
-
Yale UniversityMedtronicWithdrawn
-
Seattle Children's HospitalMedtronic; The Gerber FoundationUnknownDiabetes Mellitus, Type IUnited States
-
Postgraduate Institute of Medical Education and...RecruitingType1 Diabetes MellitusIndia
-
Medtronic DiabetesCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States
-
HealthPartners InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Yale... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States, Germany, Slovenia, Israel
-
Medtronic DiabetesCompletedDiabetes Mellitus, Type 1Netherlands, Slovenia, Denmark, Austria, Italy, Luxembourg, Spain
-
Norwegian University of Science and TechnologyNorwegian Diabetes AssociationCompletedDiabetes Mellitus, Type 1Norway
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States
-
University of CataniaCompleted